Who are the top shareholders of the Syncom Formul.?

The top shareholders of Syncom Formul include promoters led by Kedarmal Shankarlal Bankda, who holds 12.44%, and individual investors with a collective stake of 45.2%. Foreign institutional investors hold 0.11%, while mutual funds have a negligible presence, and there are no pledged promoter holdings.

The top shareholders of Syncom Formul include the promoters, who hold the majority of the shares. The promoter with the highest holding is Kedarmal Shankarlal Bankda, with a stake of 12.44%. Additionally, individual investors collectively hold 45.2% of the shares. There are also 12 foreign institutional investors (FIIs) that hold a small portion, totaling 0.11%, while mutual funds have a negligible presence with 2 schemes holding 0.0%. There are no pledged promoter holdings reported.

What does Syncom Formul. do?

Syncom Formulations (India) Ltd is a small-cap company in the Pharmaceuticals & Biotechnology sector, reporting net sales of ₹149 Cr and a net profit of ₹18 Cr for Q1 2025. It has a market cap of ₹1,960 Cr, a P/E ratio of 40.00, and a return on equity of 14.44%.

Overview: <BR>Syncom Formulations (India) Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Small Cap company.<BR><BR>History: <BR>The company was incorporated in 1988 and transitioned from a private limited company to a public limited company in June 1992. The latest quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot: <BR>Net Sales: 149 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 18 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: Rs 1,960 Cr (Small Cap)<BR><BR>Key Metrics: <BR>P/E: 40.00 <BR>Industry P/E: 35 <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.25 <BR>Return on Equity: 14.44% <BR>Price to Book: 5.82<BR><BR>Contact Details: <BR>Address: 7 Niraj Indl Estate Andheri(E), Off Mahakali Caves Rd Mumbai Maharashtra : 400093 <BR>Tel: 91-22-30887744 <BR>Email: info@sfil.in / finance@sfil.in <BR>Website: http://www.sfil.in

When is the next results date for Syncom Formul.?

No Upcoming Board Meetings

What is the bonus history of the Syncom Formul.?

Syncom Formulations (India) Ltd announced a bonus issue on August 19, 2013, in the ratio of 5:2, meaning shareholders received five additional shares for every two shares held, with a record date of August 20, 2013.

Syncom Formulations (India) Ltd has a bonus history that includes a significant bonus issue announced on August 19, 2013. The company issued a bonus in the ratio of 5:2, with the record date for this bonus being August 20, 2013. This means that for every two shares held, shareholders received five additional shares. If you have any more questions about the company or its financial activities, feel free to ask!

Has Syncom Formul. declared dividend?

Yes, Syncom Formulations (India) Ltd has declared a 3% dividend, amounting to ₹0.03 per share, with an ex-date of September 9, 2022. However, the dividend yield is 0%, as it has not significantly contributed to returns, which have been primarily driven by strong price performance over various periods.

Syncom Formulations (India) Ltd has declared a 3% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 3%<BR>- Amount per share: 0.03<BR>- Ex-date: 09 Sep 2022<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -6.22%, the dividend return was 0%, leading to a total return of -6.22%.<BR><BR>Over the past year, the price return was 74.02%, with a dividend return of 0%, resulting in a total return of 74.02%.<BR><BR>In the last 2 years, the price return was 197.45%, the dividend return was 0%, culminating in a total return of 197.45%.<BR><BR>For the 3-year period, the price return was 142.43%, with a dividend return of 0.39%, giving a total return of 142.82%.<BR><BR>In the 4-year span, the price return was 150.84%, the dividend return was 0.37%, leading to a total return of 151.21%.<BR><BR>Over the last 5 years, the price return was 1789.19%, with a dividend return of 1.46%, resulting in a total return of 1790.65%.<BR><BR>Overall, while Syncom Formulations has declared a dividend, the yield remains at 0%, indicating that the dividend has not significantly contributed to returns in recent periods. The company has shown strong price returns over various periods, particularly in the long term.

Who are the peers of the Syncom Formul.?

Syncom Formul.'s peers include Sun Pharma, Divi's Lab, Cipla, and Dr Reddy's Labs, among others. While Syncom Formul. has average management risk and below-average growth, it boasts a 1-year return of 78.13%, outperforming its peers.

Peers: The peers of Syncom Formul. are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Amrutanjan Healt, Windlas Biotech, Sigachi Indust., Solara Active, and Beta Drugs Ltd.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, and the rest. Good management risk is found at Divi's Lab., Torrent Pharma, Amrutanjan Healt, and the rest. Average management risk is noted for Syncom Formul., Windlas Biotech, Sigachi Indust., and the rest, while below average management risk is present at Solara Active. Growth is excellent for Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while below average growth is seen at Divi's Lab., Torrent Pharma, Amrutanjan Healt, Syncom Formul., Windlas Biotech, Sigachi Indust., and the rest. Excellent capital structure is noted for Sun Pharma.Inds., Divi's Lab., Cipla, Dr Reddy's Labs, Amrutanjan Healt, Syncom Formul., Windlas Biotech, Sigachi Indust., and the rest, while good capital structure is found at Torrent Pharma, and below average capital structure is observed at Solara Active.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Divi's Lab. at 51.96%, while the peer with the lowest is Solara Active at 17.81%. Syncom Formul.'s 1-year return of 78.13% is higher than both. Additionally, Windlas Biotech, Sigachi Indust., and Solara Active have negative six-month returns.

Who are in the management team of Syncom Formul.?

As of March 2023, the management team of Syncom Formul includes Kedarmal Bankda (Chairman & Wholetime Director), Vijay Shankarlal Bankda (Managing Director), and several independent directors, including Vinod Kumar Kabra and Rinki Bankda (Whole-time Director), among others. This diverse team oversees the company's governance and strategic direction.

As of March 2023, the management team of Syncom Formul includes the following members:<BR><BR>1. Kedarmal Bankda - Chairman & Wholetime Director<BR>2. Vijay Shankarlal Bankda - Managing Director<BR>3. Vinod Kumar Kabra - Independent Director<BR>4. Krishna Das Neema - Independent Director<BR>5. Praveen Jindal - Independent Director<BR>6. Rinki Bankda - Whole-time Director<BR>7. Ruchi Jindal - Independent Director<BR>8. Vaishali Agrawal - Company Secretary & Compliance Officer<BR>9. Ritesh Kumar Lunkad - Independent Director<BR>10. Ankit Jain - Independent Director<BR><BR>This team comprises a mix of executive and independent directors, contributing to the governance and strategic direction of the company.

How big is Syncom Formul.?

As of 24th July, Syncom Formulations (India) Ltd has a market capitalization of 1,723.00 Cr, with recent net sales of 465.01 Cr and a net profit of 49.43 Cr over the last four quarters.

As of 24th July, <BR><BR>Market Cap: Syncom Formulations (India) Ltd has a market capitalization of 1,723.00 Cr, categorizing it as a Small Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 465.01 Cr, while the sum of Net Profit for the same period is 49.43 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period is March 2024, with Shareholder's Funds amounting to 288.14 Cr and Total Assets valued at 404.66 Cr.

Are Syncom Formul. latest results good or bad?

Syncom Formulations reported strong year-on-year growth with net sales up 64.23% and profit after tax increasing by 27.2%. However, quarter-on-quarter declines in sales and profit, along with a 'Sell' rating from MarketsMOJO, indicate a cautious outlook.

Syncom Formulations has reported a mixed financial performance for the quarter ending June 2025. On the positive side, the company achieved net sales of Rs 265.78 crore, which represents a substantial year-on-year growth of 64.23%. Additionally, the profit after tax (PAT) increased to Rs 15.72 crore, reflecting a growth of 27.2% compared to the average PAT of the previous four quarters. These figures suggest a strong near-term sales outlook and improving financial health.<BR><BR>However, when looking at the quarter-on-quarter performance, there are some concerning trends. Net sales decreased by 21.48% compared to the previous quarter, and the consolidated net profit also fell by 10.97%. This decline in key metrics indicates a potential slowdown in momentum.<BR><BR>Furthermore, despite the positive year-on-year growth, the stock is currently rated as 'Sell' by MarketsMOJO, and the company's score has dropped significantly from 34 to 17 in the last three months. This rating reflects some market concerns about the company's overall position.<BR><BR>In summary, while Syncom Formulations has shown strong year-on-year growth, the recent quarter-on-quarter declines and market sentiment suggest a more cautious outlook.

Is Syncom Formul. technically bullish or bearish?

As of November 4, 2025, the market trend has shifted to a moderate bearish stance, driven by bearish MACD, Bollinger Bands, moving averages, and KST indicators, despite a mildly bullish signal from Dow Theory.

As of 4 November 2025, the technical trend has changed from mildly bearish to bearish. The current stance is bearish with a moderate strength. Key indicators driving this include a bearish MACD on the weekly timeframe, bearish Bollinger Bands on both weekly and monthly timeframes, and bearish moving averages on the daily timeframe. The KST is also bearish on the weekly chart, contributing to the overall bearish sentiment. The Dow Theory shows a mildly bullish signal on the weekly, but this is overshadowed by the predominant bearish indicators.

How has been the historical performance of Syncom Formul.?

Syncom Formul. has experienced significant fluctuations in financial performance, with net sales increasing to 465.01 Cr in March 2025 from 263.39 Cr in March 2024, but down from a peak of 21,966.32 Cr in March 2022. Despite recent improvements in key metrics, the company's historical data reflects volatility.

Answer:<BR>The historical performance of Syncom Formul. shows significant fluctuations in key financial metrics over the years.<BR><BR>Breakdown:<BR>Syncom Formul. reported net sales of 465.01 Cr for the year ending March 2025, a substantial increase from 263.39 Cr in March 2024 and 224.25 Cr in March 2023. However, this is a stark contrast to the exceptionally high net sales of 21,966.32 Cr recorded in March 2022. The company's total operating income mirrored this trend, reaching 465.01 Cr in March 2025, up from 263.39 Cr in the previous year. The total expenditure, excluding depreciation, was 410.88 Cr in March 2025, which also increased from 233.74 Cr in March 2024. Operating profit (PBDIT) for March 2025 was 71.56 Cr, showing a rise from 43.18 Cr in March 2024, while profit before tax was reported at 65.51 Cr, up from 33.95 Cr. The profit after tax for March 2025 was 49.43 Cr, compared to 25.31 Cr in March 2024. The earnings per share (EPS) improved to 0.53 in March 2025 from 0.27 in March 2024. On the balance sheet, total assets increased to 413.28 Cr in March 2025 from 404.66 Cr in March 2024, while total liabilities also rose to 413.28 Cr from 404.66 Cr. The cash flow from operating activities was positive at 23.00 Cr in March 2025, a recovery from a negative cash flow of -5.00 Cr in March 2024. Overall, while Syncom Formul. has shown improvement in several financial metrics in the latest fiscal year, the historical data reflects a volatile performance with significant peaks and troughs.

Should I buy, sell or hold Syncom Formul.?

Is Syncom Formul. overvalued or undervalued?

As of November 18, 2025, Syncom Formul. is fairly valued with a PE ratio of 24.53, compared to its peers like Sun Pharma at 36.56 and Cipla at 22.49, indicating reasonable pricing relative to its earnings growth potential despite underperforming the Sensex year-to-date.

As of 18 November 2025, the valuation grade for Syncom Formul. has moved from expensive to fair. The company is currently fairly valued, with a PE ratio of 24.53, an EV to EBITDA ratio of 21.00, and a PEG ratio of 0.27. These ratios suggest that while the company is priced reasonably compared to its earnings growth potential, it is not undervalued.<BR><BR>In comparison to its peers, Syncom Formul. stands out against Sun Pharma, which is considered expensive with a PE ratio of 36.56, and Cipla, which is attractive with a PE ratio of 22.49. The fair valuation of Syncom Formul. indicates that it is positioned well within the industry, especially when compared to the higher valuations of some competitors. Notably, while the stock has underperformed the Sensex year-to-date, it has shown significant returns over longer periods, reflecting its potential for growth.

Which are the latest news on Syncom Formul.?

Why is Syncom Formul. falling/rising?

As of 04-Dec, Syncom Formulations (India) Ltd's stock price is slightly rising at 15.38, following three days of decline, but it remains down 23.10% year-to-date. Despite today's uptick and increased investor participation, the stock is trading below its moving averages, indicating ongoing bearish sentiment.

As of 04-Dec, Syncom Formulations (India) Ltd's stock price is experiencing a slight rise, currently at 15.38, with a change of 0.02 (0.13%) upward. This increase comes after three consecutive days of decline, indicating a potential trend reversal. Despite the recent uptick, the stock has been underperforming over various time frames, with a year-to-date decline of 23.10% compared to a 9.12% gain in the Sensex. <BR><BR>The stock's performance today is reported to be in line with its sector, and there has been a notable increase in investor participation, with delivery volume rising by 10.14% against the five-day average. However, it is important to note that Syncom Formulations is trading below its moving averages across multiple time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, which suggests continued bearish sentiment in the longer term. <BR><BR>Overall, while there is a minor rise in the stock price today, the broader context indicates ongoing challenges for Syncom Formulations, as evidenced by its significant declines over the past month and year.